Monthly Archives: February 2011

Battling Chronic Disease in Mexico

The objectives of the Workplace Wellness & Prevention Council of Mexico could lead to a win-win situation that may serve as a model for other developing countries around the world. In 2003, Abner Mason started a non-profit in Mexico. The AIDS Responsibility Project’s primary function was to campaign against discrimination of people with AIDS and […]
Posted in Emerging Markets, Global, healthcare | Tagged , , | 4 Comments

Europe Unites Over Counterfeiting

Imitation may the sincerest form of flattery, but it isn’t always welcome. Particularly when the imitations are fakes through and through. That explains why Europe’s new rules to combat counterfeit medicines are winning such widespread applause, says Reflector. It isn’t customary for European Union legislation to win backing from all sides. Usually, there’s a large […]
Posted in Europe, Global, Guest Blog, Supply Chain | Tagged , , | Leave a comment

Croatia: A New Hope for European Pharma?

With Croatia’s potential accession to the EU gathering pace, Beth Kennedy looks at the implications for pharma. The growth in overall healthcare expenditure in Croatia is slow and the percentage of GDP is expected to remain the same, but the country’s accession to the EU means that European pharma would have access to cheap products […]
Posted in Emerging Markets, Europe, Global, Guest Blog, healthcare, Market Access | Tagged , , | Leave a comment

Is Sanofi Right to Bank on MS Drug?

Newswires have long been waiting for Sanofi-Aventis to officially announce its acquisition of US biotech company Genzyme, but what few analysts were expecting is just how much the transaction would hedge on one potentially controversial product. As the focus of Sanofi’s contingent value rights (CVR) approach, Genzyme’s multiple sclerosis treatment Lemtrada (also sold as Campath […]
Posted in pricing, Safety, Strategy | Tagged , , , , , | 1 Comment

FDA Approvals Down on Last Two Years

A new FDA report summarizes the new drug approvals for 2010, and highlights some surprising numbers compared to years past. According to a recent FDA report, FDA’s Center for Drug Evaluation and Research (CDER) approved 21 New Molecular Entities (NMEs) in 2010, which is less than in 2009 (26) and 2008 (24), but greater than […]
Posted in FDA, Regulatory | Tagged , | 1 Comment
  • Categories

  • Meta